Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Procter & Gamble will shut down business in Pakistan, following Shell and Pfizer exits
2/10/2025
Dubai real estate market 2025 : A thriving global investment hub
2/10/2025
Only 9.5% of Indian households invest despite 63% market awareness : Sebi survey
2/10/2025
Dussehra 2025 : 45 multibagger stocks deliver up to 11,400% returns in 1 year
2/10/2025
Sebi nod to Nuvama's mutual fund entry, approves role as sponsor
2/10/2025
'There will always only be one Jane Goodall'
2/10/2025
